We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A panel of arthritis experts has overwhelmingly recommended against the approval of Johnson & Johnson's sirukumab. The panel voted 12 to 1 against approving the IL-6 monoclonal antibody for the treatment of rheumatoid arthritis after taking a dim view of